Veterinary oncology programme: tigilanol tiglate

Tigilanol tiglate, branded as STELFONTA®, is approved and marketed as a veterinary pharmaceutical for treatment of non-metastatic, canine mast cell tumours1,2  in the European Union, Switzerland, United Kingdom, Australia and United States of America. (this link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.)

STELFONTA® is marketed and distributed in these jurisdictions through a partnership with Virbac, a global animal health company.

Tigilanol tiglate was efficacious and well-tolerated in a randomised clinical trial

In a multicentre, randomised, blinded and controlled field efficacy study in the USA conducted in 123 dogs, a single intratumoural injection of tigilanol tiglate resulted in complete resolution (Complete Response) of the treated mast cell tumours in 75% of patients1 (see figure below).  For dogs that did not fully respond, a second tigilanol tiglate treatment increased the Complete Response rate to 87%, with no local tumour recurrence in 93% of dogs at 84 days post treatment3 and no recurrence in 89% of evaluable cases at 12 months post treatment4.

Importantly, tigilanol tiglate was very well tolerated and animals had a good quality of life during and after treatment.2

Further clinical trials are in progress in Australia, the USA, Europe and the UK to determine efficacy of tigilanol tiglate in other solid tumours and species.

A single treatment with tigilanol tiglate (STELFONTA®) induces a Complete Response in 75% of mast cell tumours (p<0.0001)3